Wednesday, June 7, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

Multicenter Program for Botulinum Neurotoxin Countermeasures

by Global Biodefense Staff
October 15, 2015
Botulinum Neurotoxin Protein Structure

Botulinum Neurotoxin Protein Structure. Credit: Shutterstock

The U.S. federal government has recently extended the period of performance on three Research and Development contracts in support of a Defense Threat Reduction Agency (DTRA) biodefense consortium project.

The consortium is for the Development of Medical Countermeasures for Botulinum Neurotoxin Intoxication Focused on Therapeutics and Neuroregenerative Medicines, a multicenter program in which directed research projects are submitted, evaluated and selected to sponsor a network of collaboration amongst researchers.

Under the multicenter collaboration, three proposals were selected to be administered in coordination with U.S Army Medical Research Institute of Chemical Defense (USAMRICD) collaborators:

Montclair State University: Contributing to the botulinum drug discovery effort by synthesizing small molecule drug candidates for treatment of botulinum toxin exposure and optimizing their pharmaceutical properties.

Institute of Advanced Sciences: Supports the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) by performing high throughput screening of natural product and small molecule libraries.

Ossianix Inc: Providing an alternative to traditional inhibitors by developing small single chain shark antibodies as potential inhibitors for catalytic activity.

MSU and the Institute for Advanced Sciences will each receive an additional $75,000 to support completion of activities in 2015 under the first research cycle of the consortium. Ossianix will be receiving a completion date extension using the funding made available at the time of initial contract. The three research contracts will end on December 31, 2015.

Research contracts to be performed in Fiscal Year 2016 to support the development of medical countermeasures will be addressed competitively through the U.S Army Medical Research and Materiel Command’s (USAMRMC) Broad Agency Announcement.

Tags: AntitoxinsAwardsBotulinum NeurotoxinDefense Threat Reduction Agency

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC